MENU
+Compare
CMOPF
Stock ticker: OTC
AS OF
Feb 3 closing price
Price
$168.43
Change
+$85.38 (+102.81%)
Capitalization
2.7B

CMOPF stock forecast, quote, news & analysis

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech... Show more

CMOPF
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CMOPF with price predictions
Feb 03, 2026

CMOPF in downward trend: price expected to drop as it breaks its higher Bollinger Band on February 03, 2026

CMOPF broke above its upper Bollinger Band on February 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 7 similar instances where the stock broke above the upper band. In of the 7 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 20, 2026. You may want to consider a long position or call options on CMOPF as a result. In of 22 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CMOPF just turned positive on February 03, 2026. Looking at past instances where CMOPF's MACD turned positive, the stock continued to rise in of 20 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CMOPF advanced for three days, in of 12 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 87 cases where CMOPF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating for company is (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.236) is normal, around the industry mean (9.409). P/E Ratio (40.001) is within average values for comparable stocks, (24.389). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.865). Dividend Yield (0.014) settles around the average of (0.025) among similar stocks. CMOPF's P/S Ratio (12.804) is very high in comparison to the industry average of (3.952).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CMOPF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 114.29B. The market cap for tickers in the group ranges from 72.83K to 898.12B. LLY holds the highest valuation in this group at 898.12B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -0%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 18%. AZN experienced the highest price growth at 93%, while NONOF experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 156% and the average quarterly volume growth was 39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 28
P/E Growth Rating: 65
Price Growth Rating: 48
SMR Rating: 55
Profit Risk Rating: 72
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
CMOPF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Sir John Rogerson’s Quay
Phone
+353 18170370
Employees
295
Web
https://www.cosmopharma.com